Positron Emission Tomography–Computed Tomography (PET-CT) is an advanced hybrid imaging modality that integrates metabolic and anatomic information to improve disease detection, staging, response assessment, and surveillance. The core principle is functional imaging based on radiotracer uptake, most commonly 18F-fluorodeoxyglucose (18F-FDG), a glucose analog. After intravenous administration, FDG is transported into cells and phosphorylated to FDG-6-phosphate; because it is not readily further metabolized, its intracellular retention reflects relative glycolytic activity. Tumors often demonstrate increased glucose metabolism due to oncogenic signaling, hypoxia-driven pathways, and altered cellular energetics, producing higher tracer uptake than surrounding tissues.
PET-CT consists of two components acquired in a single session. PET provides three-dimensional tracer distribution, while CT supplies high-resolution morphology and attenuation correction for PET quantification. The fused datasets allow clinicians to localize areas of abnormal metabolic activity to specific anatomic structures. Modern reconstruction and attenuation correction can produce standardized uptake values (SUVs), which are semi-quantitative metrics used to monitor disease burden and therapy response. SUVmax (maximum SUV) and measures such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) can provide additional context, particularly in heterogeneous lesions.
In oncology, PET-CT is widely used for multiple indications. For initial staging of many solid malignancies, it can identify occult metastatic disease that is not visible on conventional imaging. In lung cancer, PET-CT evaluates mediastinal and distant spread, guiding decisions regarding surgery, radiation fields, and systemic therapy. For head and neck cancers, it helps detect nodal disease and distant metastases while differentiating tumor recurrence from post-treatment fibrosis. In colorectal cancer and lymphomas, PET-CT assists in staging and can influence treatment strategy by detecting metabolically active nodes or lesions. During treatment, PET-CT may support early response evaluation, such as interim assessments in certain lymphoma protocols.
For therapy monitoring and surveillance, PET-CT can distinguish viable, metabolically active tumor from residual scar tissue that may persist on CT. However, interpretation requires caution: post-therapy inflammatory changes can increase FDG uptake (false positives), and low-grade or indolent tumors may show limited FDG avidity (false negatives). Additional radiotracers beyond FDG are sometimes employed, including amino acid tracers for specific brain and neuroendocrine applications, and other agents tailored to disease biology.
Preparation is essential for reliable results. Standard practice includes patient fasting for several hours prior to FDG administration to reduce physiological glucose and insulin levels, thereby improving tumor-to-background contrast. Blood glucose is measured before tracer injection; hyperglycemia can compete with FDG and decrease lesion detectability. Patients are often instructed to avoid strenuous exercise prior to scanning, since muscular activity increases uptake and may create diagnostic confusion. Hydration and good bladder emptying can reduce pelvic tracer retention artifacts.
Radiation exposure is a key consideration. PET-CT involves ionizing radiation from both the PET radiotracer and the CT acquisition. Clinicians weigh the expected diagnostic benefit against risk, aiming to minimize CT dose with protocols such as tube current modulation and appropriate scan length. When clinically appropriate, alternative imaging strategies may be considered, but for many oncologic indications the incremental value of PET-CT is substantial.
Interpretation is based on pattern recognition integrating SUV, lesion morphology, distribution, and clinical context. Benign processes—such as infection, granulomatous disease, and recent surgery—may show increased FDG uptake. Temporal factors matter: acute inflammation can mimic malignancy, and early post-therapy scans may yield transient positivity. Conversely, certain malignancies (e.g., some low-grade tumors, mucinous histology, and lesions with low metabolic activity) may be less FDG-avid. Therefore, PET-CT findings often require correlation with histopathology, MRI, CT follow-up, or biopsy when uncertainty persists.
Biologically, FDG uptake reflects not only proliferation but also microenvironmental influences including hypoxia, inflammatory infiltration, and metabolic reprogramming. Tumor heterogeneity contributes to variable uptake, and partial volume effects can affect small lesions. Quantification with SUVs must be standardized with attention to dosing, body weight versus lean body mass normalization, time from injection to imaging, scanner calibration, and reconstruction parameters.
Despite limitations, PET-CT remains a cornerstone in contemporary precision oncology because it links disease biology to actionable clinical decisions. Its hybrid design accelerates workflows by providing integrated localization and reduces the need for separate imaging sessions. As imaging science advances, more robust quantification strategies, radiomics, and theranostic approaches with novel tracers are expanding the clinical utility of PET-CT beyond conventional FDG-based assessment. Source: [MoHFW_INDIA] (original post by @MoHFW_INDIA on Jun 2, 2026).
Ministry of Health: Advancing healthcare services and medical excellence at AIIMS Bathinda. Union Health Minister Shri Jagat Prakash Nadda attended the 2nd Convocation Ceremony of AIIMS Bathinda and inaugurated the Burn ICU, PET-CT facility, High Energy Linear Accelerator (HELA), Child Development. #breaking
— @MoHFW_INDIA May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
